Monitoring clinical progression with mitochondrial disease biomarkers
Open Access
- 3 August 2017
- journal article
- review article
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (10) , 2530-2540
Abstract
Mitochondrial disorders are genetically determined metabolic diseases due to a biochemical deficiency of the respiratory chain. Given that multi-system involvement and disease progression are common features of mitochondrial disorders they carry substantial morbidity and mortality. Despite this, no disease-modifying treatments exist with clear clinical benefits, and the current best management of mitochondrial disease is supportive. Several therapeutic strategies for mitochondrial disorders are now at a mature preclinical stage. Some are making the transition into early-phase patient trials, but the lack of validated biomarkers of disease progression presents a challenge when developing new therapies for patients. This update discusses current biomarkers of mitochondrial disease progression including metabolomics, circulating serum markers, exercise physiology, and both structural and functional imaging. We discuss the advantages and disadvantages of each approach, and consider emerging techniques with a potential role in trials of new therapies.Keywords
Funding Information
- National Institutes of Health
- Wellcome Trust
- NIHR
- Medical Research Council (MR/N025431/1)
- European Research Council (309548)
- Newton Fund (UK/Turkey, MR/N027302/1)
- GlaxoSmithKline
This publication has 130 references indexed in Scilit:
- Defining cardiac adaptations and safety of endurance training in patients with m.3243A>G-related mitochondrial diseaseInternational Journal of Cardiology, 2013
- Muscle MRI reveals distinct abnormalities in genetically proven non-dystrophic myotoniasNeuromuscular Disorders, 2013
- Cardiomyopathy is common in patients with the mitochondrial DNA m.3243A>G mutation and correlates with mutation loadNeuromuscular Disorders, 2012
- Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopyMagnetic Resonance in Medicine, 2011
- miRNAs as serum biomarkers for Duchenne muscular dystrophyEMBO Molecular Medicine, 2011
- Exercise Capacity and Idebenone Intervention in Children and Adolescents With Friedreich AtaxiaArchives of Physical Medicine and Rehabilitation, 2010
- Noninvasive Detection of Target Modulation following Phosphatidylinositol 3-Kinase Inhibition Using Hyperpolarized 13C Magnetic Resonance SpectroscopyCancer Research, 2010
- Neuroimaging of mitochondrial diseaseMitochondrion, 2008
- The in-depth evaluation of suspected mitochondrial diseaseMolecular Genetics and Metabolism, 2008
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001